Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

51.77 +0.20 (+0.39%)
Streaming Delayed Price Updated: 10:08 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
34 35 Next >
News headline image
6 ETFs That Are All You Need for Retirement ↗
These yield-producing stock and bond funds are all down less than the S&P 500 this year. 
Via The Motley Fool
News headline image
15 Global Psychedelics Executives To Keep An Eye On In 2022 ↗
As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list... 
Via Benzinga
News headline image
Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
By Jad Malaeb, Benzinga 
Via News Direct
Topics ETFs Stocks
Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ) and the SPDR Dow Jones Industrial Average... 
Via TheNewswire.com
Topics ETFs Stocks
News headline image
Biogen To Report Q3 Earnings: Here's What To Expect ↗
Biogen will report third-quarter 2022 results on Oct 25, before market open. 
Via Talk Markets
News headline image
Most Active On The OTC Markets In September – A Look Back As October Comes To A Close ↗
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022. 
Via Benzinga
News headline image
Positive Topline Phase III Results Show Genentech’s Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO)
From Genentech
Via Business Wire
News headline image
Early Treatment With Genentech’s Ocrevus (ocrelizumab) Leads to Reduced Disease Progression and Healthcare Costs; Nine-Year Safety Data Reinforce Favorable Benefit-Risk Profile
From Genentech
Via Business Wire
News headline image
Analyst Bullish On SQZ Biotech's Technology For Solving Cell Therapy Challenges ↗
 
Via Benzinga
News headline image
Genentech to Present New Ocrevus (ocrelizumab) Data in Multiple Sclerosis and Continued Research Into Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2022
From Genentech
Via Business Wire
News headline image
Roche Posts Lower Quarterly Sales As Demand For COVID Products Slide ↗
 
Via Benzinga
News headline image
Market Sentiment Improves Amid Earnings Season ↗
The fourth quarter started on a sour note as geopolitical tensions and recession fears triggered a risk-averse mood, but earnings season has started since then, focusing market participants’ attention... 
Via Talk Markets
News headline image
Week In Review: Jemicare Out-Licenses Prostate Cancer Therapy To Roche For $650 Million ↗
Deals, financings, trials and approvals on the China biotech/pharma market. 
Via Talk Markets
News headline image
Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts ↗
Stifel upgraded Biogen Inc (NASDAQ: BIIB) from Hold to Buy, saying shares have faded since positive lecanemab data in mild Alzheimer's. 
Via Benzinga
News headline image
Biogen Soars On Upgrade; Why Lilly, Roche Won't Block Its Alzheimer's Opportunity ↗
Even a percentage of the Alzheimer's market could mean $7 billion for Biogen. 
Via Investor's Business Daily
News headline image
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients ↗
 
Via Benzinga
News headline image
Roche To Introduce Next-Generation Portfolio Of COVID-19 Rapid Tests ↗
 
Via Benzinga
News headline image
Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
News headline image
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers ↗
 
Via Benzinga
News headline image
EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility ↗
Lineage Cell Therapeutics Inc (NYSE: LCTX) has opened a new research and development facility in Carlsbad, California. 
Via Benzinga
News headline image
Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review ↗
The major indexes fell, with the S&P 500 breaking below bear market lows. 
Via Investor's Business Daily
News headline image
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win ↗
 
Via Benzinga
News headline image
This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval ↗
 
Via Benzinga
News headline image
2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data ↗
Biogen Inc. (NASDAQ: BIIB) and partner Eisai Co. Ltd. 
Via Benzinga
News headline image
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests ↗
 
Via Benzinga
News headline image
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns ↗
The World Health Organization (WHO) warned that it struggles to identify and 
Via Benzinga
News headline image
Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger ↗
 
Via Benzinga
News headline image
Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders ↗
 
Via Benzinga
News headline image
WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete ↗
Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies. 
Via Benzinga
News headline image
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.